Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02380716 · ClinicalTrials.gov registry record

ARISE: Evaluation of the GORE® Ascending Stent Graft in the Treatment of DeBakey Type I/II Aortic Dissection

A clinical trial of Aortic Dissection, sponsored by W.L.Gore & Associates.

Active
Registry status
21
Enrollment target
1
Study location

NCT02380716: Active study of Aortic Dissection, sponsored by W.L.Gore & Associates.

NCT02380716 is a study of Aortic Dissection that is active but no longer recruiting, run by W.L.Gore & Associates. The registered enrollment target is 21 participants, below the 662-participant average among 11 other Aortic Dissection trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02380716, a study of Aortic Dissection, is active but no longer recruiting, sponsored by W.L.Gore & Associates.

ACTIVE NOT RECRUITING
Registry status
21 participants
Enrollment target
1
Study location

Study Summary

Assess the feasibility of the treatment of DeBakey Type I/II aortic dissections with the GORE® Ascending Stent Graft

Primary Outcome

Number of subjects that die of any cause within 30 days post-procedure

Conditions Studied

Interventions

  • DEVICE GORE® Ascending Stent Graft

Study Locations (1)

California

  • University of Southern California- Keck Medicine - Los Angeles

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2015-08
Est. Completion 2026-04
W.L.Gore & Associates

53 total trials

What the registry record for NCT02380716 still lists

NCT02380716 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 662-participant average among 11 other Aortic Dissection trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Aortic Dissection appearing as the primary indexed condition, and to 1 intervention - of which GORE® Ascending Stent Graft is the first listed.

NCT02380716 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT02380716 about?

NCT02380716 is a clinical study titled "ARISE: Evaluation of the GORE® Ascending Stent Graft in the Treatment of DeBakey Type I/II Aortic Dissection". Assess the feasibility of the treatment of DeBakey Type I/II aortic dissections with the GORE® Ascending Stent Graft

What is the current status of trial NCT02380716?

This trial is currently active not recruiting. The enrollment target is 21 participants. The study started on 2015-08. Estimated completion is 2026-04.

What conditions does trial NCT02380716 study?

This clinical trial studies the following conditions: Aortic Dissection.

What interventions are being tested in trial NCT02380716?

The interventions under investigation include: GORE® Ascending Stent Graft (DEVICE).

Who is sponsoring clinical trial NCT02380716?

This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02380716 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aortic Dissection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02380716's enrollment target sits among peer trials

21 11th of 11 higher than 1 of 11 other Aortic Dissection trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Aortic Dissection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02380716, the US trial registry maintained by the National Library of Medicine. NCT02380716 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.